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Abstract
With a diminishing number of effective antibiotics, there has been interest in developing antimicrobial peptides (AMPs) as
drugs. However, any new drug faces potential bacterial resistance evolution. Here, we experimentally compare resistance
evolution in Staphylococcus aureus selected by three AMPs (from mammals, amphibians and insects), a combination of two
AMPs, and two antibiotics: the powerful last-resort vancomycin and the classic streptomycin. We find that resistance evolves
readily against single AMPs and against streptomycin, with no detectable fitness cost. However the response to selection
from our combination of AMPs led to extinction, in a fashion qualitatively similar to vancomycin. This is consistent with the
hypothesis that simultaneous release of multiple AMPs during immune responses is a factor which constrains evolution of
AMP resistant pathogens.
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Introduction
Environmental microbes readily evolve direct resistance to
many powerful environmental stresses, whilst pathogenic bacteria
avoid stress imposed by the immune system by evasion or
subversion [1,2]. Antimicrobial peptides (AMPs) are components
of the immune system of multicellular organisms, and therefore
are very prevalent in the environment, that usually kill microbes by
selectively binding and disrupting prokaryotic cell membranes
[3,4]. AMPs are known to control both pathogenic [5,6] and
mutualistic [7] microbes. AMP resistance rapidly evolves at low
cost in vitro: Resistance to pexiganan can evolve at low cost within
just a few hundred generations in Escherichia coli and Pseudomonas
fuorescens [8]. Salmonella enterica can evolve resistance to protamine
and PR-39, and costs of resistance were either not observable or
reversible by compensatory mutation [5,9]. Nevertheless, suscep-
tibility is variable in natural isolates [10]. AMP resistance thus
presents a puzzling paradox: selection for resistance is widespread
and it can arise at low cost, so why does variation persist?
AMP analogues have been proposed as next-generation
antibiotics [11,12]. Since active sites of AMPs are conserved,
their putative therapeutic use stands to ‘arm the enemy’ with
resistance to immune systems [12]. This concerning hypothesis has
recently gained empirical support [13]. Understanding AMP
resistance is therefore biomedically and evolutionarily interesting.
To this end we must investigate costs and benefits of resistance to
varied simulated immunological conditions.
Previous workers have suggested that natural AMP resistance is
constrained by prohibitive intrinsic costs [3], however this is not
consistent with in vitro data [5,8,9]. In immune responses multiple
AMPs are usually transcribed after infection. Experiments in
Drosophila melanogaster showed functional redundancy in AMPs, as
fitness of flies mutant for AMP synthesis was dramatically reduced
after infection, but restored by re-expression of just one AMP [6].
This suggests that the multiplicity of AMPs transcribed after
infection serves a function other than just clearance of infection,
which we hypothesized to be curtailing resistance to any single
AMP. Biochemical studies have already demonstrated synergistic
interactions between AMPs in vitro [14].
Here, we approach this principle by comparing the evolutionary
response of the gram-positive bacterium Staphylococcus aureus (in
which AMP resistance has already been experimentally evolved
[13]) to in vitro selection from AMPs at standardised intensity, and
investigate fitness consequences. Our study has three additional
new features: (a) as AMPs are ubiquitous amongst animals we use
AMPs from phylogenetically diverse taxa (mammals, amphibians,
insects), all of which have been developed as antimicrobial drugs
(b) we study the response to selection from two combined AMPs
applied at the same intensity of selection as the parallel
constituents; (c) we compare kinetics of AMP resistance evolution
with antibiotic-selected treatment controls.
Materials and Methods
We used S. aureus JLA 513 (from Simon Foster, Sheffield) which
contains a chromosomal tetracycline resistance cassette that does
not affect transcription or growth [15].
We used three AMPs and two conventional antibiotics as
stressors. Pexiganan was kindly provided by Michael Zasloff,
Georgetown University. Pexiganan was the first AMP to be
developed for medical application [16] and kills bacteria by
forming pores [17]. Melittin (Sigma-Aldrich M2272) is a well-
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studied membrane-permeabilizing peptide originating from honey
bee venom [18,19,20]. Iseganan is a protegrin derived orginally
from pig leucocytes [21]. Iseganan was synthesised by 9-
fluorenylmethoxycarbonyl solid phase chemistry and purified on
Kromasil sorbent, as previously [22,23]. Pexiganan and melittin
were also used in a 50:50 combination (PGML): 1 mg ml21 PGML
contained 0.5 mg ml21 pexiganan and 0.5 mg ml21. Streptomycin
(Sigma-Aldrich S9137) is an antibiotic derived from common
environmental bacteria, so S. aureus is likely to have a history of
association with it, reflected by ubiquitous streptomycin-resistant
S. aureus [24]. By contrast S. aureus resistance to vancomycin
(Sigma-Aldrich V1130) is less - albeit increasingly - common [1].
Since vancomycin resistance arises almost exclusively by horizon-
tal gene transfer we predicted that vancomycin would be more
robust to S. aureus resistance evolution in our study, but
streptomycin resistance would be more facile. This allows us to
qualitatively compare the responses AMP-selection to antibiotics
that can (streptomycin) and cannot (vancomycin) be easily
overcome by S. aureus, independent of antimicrobial mechanism.
Selection protocols followed [8] and allowed opportunities for
standardized growth and evolution. All cultures were incubated at
30uC/120 rpm in SGM (standard growth medium: Mu¨ller-Hinton
Broth [Sigma-Aldrich 70192], 5 mg ml21 tetracycline, 5.6 mg ml21
amphotericin-B). Before selection (day 210) S. aureus was
inoculated into 5 ml SGM and grown for 24 h. 50 ml culture
was passaged every 24 h for 10 days (day 0) - approximately 72
generations - to allow random mutation and accumulation of
genetic diversity in our day 0 ‘‘ancestor’’ population.
Five parallel selection lines were established in each treatment at
MIC50 (see below), alongside unselected controls. 5 ml samples
(,2.86107 colony forming units) of the ancestor culture were
inoculated into 500 ml preparations of each treatment. 5 ml of 24 h
cultures were daily passaged to fresh media. OD at 595 nm
(OD595) of 100 ml of 24 h cultures were measured daily in a
microtitre plate (Fig. S1). Remainders were cryofrozen in glycerol.
Weekly, concentrations of treatment compounds were doubled
(e.g. 86MIC50 in week 4).
To check for contamination and to confirm the presence or
extinction of S. aureus, cultures were diluted and plated bi-daily on
LB 1.5% agar. Colonies displaying abnormal colour or morphol-
ogy were re-plated on selective indicator medium (Mannitol Salt
Phenol Red Agar [Sigma 63567-500G-F]) to verify that the cells
were S. aureus. These protocols revealed no contamination through
the course of the experiment. Extinction of populations was
defined as two or more days with an OD equal to that of blank
SGM, and no growth after plating onto LB 1.5% agar. Cultures
were grown until extinction or the end of week 4 (Methods S1).
Minimum concentration of each AMP and antibiotic stressor
required for total and 50% inhibition of growth (MIC and MIC50,
respectively) and basic reproductive rate (r0) [2] were determined
by dose-response assays in sterile 96-well microtitre plates, in a 2-
fold dilution series of stressors (between 256 mg ml21 to 0.125 mg
ml21, plus unsupplemented SGM for r0 estimation (Table S1)). To
prepare cultures for assay, 50 ml of each culture was taken directly
from the selection lines and grown in 5 ml SGM to late log-phase.
10 ml of culture was added to each well and OD595 was measured
Figure 1. Population extinctions during AMP/antibiotic selection monitored over 28 days. Surviving lines are compressed into the top
line of the figure.
doi:10.1371/journal.pone.0076521.g001
Selection, Antimicrobial Peptides and Antibiotics
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e76521
every hour for 6 hours, allowing exponential growth, which we
take as our fitness measure.
Dose-response assays for MIC50 determination used bacteria
from one culture of exponential-phase S. aureus JLA 513
(OD595 = 0.05). For assessment of MIC and r0 during the selection
protocol, assays were performed on subcultures taken directly from
the selection lines (50 ml selection line culture inoculated into 5 ml
unsupplemented SGM) grown for 18 h and diluted 1:10. Cultures
showing aberrant growth or atypical starting OD were excluded
from subsequent analysis post hoc.
r0 (basic reproductive/growth rate) was calculated for all
cultures (i.e. 3 technical replicates in up to 11 different
concentrations of stressor, plus unsupplemented media) in dose-
response assays. r0s were calculated by logging the input OD data
to linearise curves, and then taking the first derivative of a
smoothed spline fitted to these data, representing the steepest point
of the spline and therefore the maximum growth rate observed in
our assays.
Table 1. Fold-change in MIC/population/week (median of 3
tests/combination), relative to ancestral population.
Week
Treatment Population 1 2 3 4
Iseganan 1 8 .8 4 .16
2 8 .8 4 .16
3 8 8 ** .16
4 8 8 4 .16
5 8 8 4 .16
Melittin 1 4 4 8 32
2 2 2 8 4
3 2 4 8 4
4 2 2 16 16
5 2 16 16 16
Pexiganan 1 8 8 l l
2 8 8 l l
3 8 4 l l
4 4 8 l l
5 8 4 l l
Pexiganan &
melittin 50:50
1 2 1 e e
2 2 ** e e
3 4 4 e e
4 2 4 e e
5 4 2 e e
Vancomycin 1 .64 32 e e
2 .64 .64 e e
3 .64 8 e e
4 .64 32 e e
5 .64 32 e e
Streptomycin 1 .8 .8 .16 .16
2 .8 .8 .16 .16
3 .8 .8 .16 .16
4 .8 .8 .16 .16
5 .8 .8 .16 .16
Zero observed inhibition is denoted by indication of MIC greater than the fold-
change in MIC that would be inferred by MIC at the greatest concentration of
stressor assayed.
**data excluded due to low OD upon inoculation into MIC assays.
l: low-density (pexiganan) and e: extinct cultures.
doi:10.1371/journal.pone.0076521.t001
Figure 2. Weekly fitness indices of selected populations. Fitness
indices were calculated as basic reproductive rate (R0) of each
population (medians, n = 3) divided by average weekly R0. Pexiganan-
selected cultures are excluded from weeks 3 and 4. Vancomycin and
PGML-selected cultures were extinct by the end of week 3. 2-way
ANOVA (week x treatment): F = 2.2, df = 14, p,0.01. At the end of week
2, only PGML showed significantly depressed fitness relative to the
other populations (Tukey post-hoc comparisons: piseganan = 0.03, pme-
littin = 0.02, ppexiganan = 0.0005, pstreptomycin = 0.0003).
doi:10.1371/journal.pone.0076521.g002
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MIC50 was determined with the R package Grofit [25].
Bootstrapped smoothed splines were fitted to each growth curve
and m values were estimated. m was used to construct dose-
response curves, from which MIC (end weeks 1–4) and MIC50
(day 210) were estimated. Weekly fold-change in MIC of each
culture was calculated. r0 was taken as median m in unsupple-
mented media (See Methods S1[S3]). MIC was estimated as the
first concentration in which there was no observable 6 h growth.
To calculate relative fitness indices, we took the mean of our
measurements of r0 in unsupplemented medium of the three
technical replicates of each of surviving populations per treatment
per week. Since we expect some adaptation by all cultures to our
protocols and experimental conditions, mean r0 values were of
each population were normalised to the mean r0 of all populations
in each respective week, to visualise how the fitness of each
individual population changed.
Results and Discussion
All unselected procedural controls survived the duration of the
experiment (Figure S1). PGML-selected cultures showed the
earliest extinctions of all treatments (Figure 1) suggesting that
simultaneous evolutionary responses to two stressors with different
killing mechanisms was overwhelmingly challenging. Of the singly-
selected cultures, iseganan- and melittin-selected cultures survived
the duration of the experiment. Two pexiganan-selected cultures
went extinct in week 4, when others were at low density (Methods
S1). As predicted, viable streptomycin-selected cultures persisted
for the duration of the experiment, and vancomycin-selected
cultures went rapidly extinct in week 3. By this measure, melittin
and iseganan presented the same evolutionary challenge as
streptomycin. Crucially, our combined AMP (PGML) treatment
led to more rapid extinction than any other treatment.
The evolution of resistance varied by treatment (Table 1).
PGML-selected populations showed 1-4-fold greater resistance
than the ancestor at the end of week 2, compared to 2-16-fold in
mellitin- and 4-8-fold greater resistance in pexiganan-selected
groups. Pexiganan-selected populations showed elevated MIC up
to the end of week 2 (Methods S1). Iseganan- and melittin-selected
populations showed steady increases in MIC throughout the
course of the experiment. By the end of the experiment, iseganan-
selected cultures were not inhibited by any concentration of
iseganan up to 125 ml mg21, in common with streptomycin-
selected cultures. In contrast, vancomycin-selected bacteria
showed stark increases in MIC over weeks 1 and 2, which is
surprising given their extinction in the middle of week 3,
highlighting that MIC assays do not always predict the robustness
of an antimicrobial treatment over time (see Methods S1).
Summarily, singly-administered AMPs can be overcome as easily
as streptomycin, whereas their effect in combination is much more
robust over time and comparable to vancomycin.
The three PGML-selected cultures that survived to the end of
week 2 showed a significant depression of fitness relative to the
three single AMPs and streptomycin at the end of week 2
(Figure 2). No other culture showed fitness costs. Since they did not
become more resistant, we interpret the fitness effect observed in
PGML-selected cultures as a lasting plastic (e.g. epigenetic)
consequence of stress in the selection protocol, following failure
to adapt to the stresses imposed by treatment, rather than an
evolutionary cost. In other treatments that became more resistant
to their stressors, we did not detect costs of resistance.
Our extinction, growth rate and resistance results are consistent
with the principle that selection from combined AMPs is different
to the sum of selection from the combination’s parts, since the
response to selection from PGML was retarded relative to
responses to the individual constituents. Technical limitations on
the volume of iseganan that we were able to produce meant that
we were unable to test this principle in a fully reciprocal design
involving all possible combinations of our three AMPs. Further
work is required to determine whether all AMPs are more robust
to resistance evolution when administered or transcribed in
combination. However we speculate that this is likely to be a
general phenomenon, which is dependent on the nature of the
functional interaction between the compounds, similar to effects of
combinatorial administration on evolution of antibiotic resistance
[26,27,28].
Consistent with previous studies [13], we were unable to detect
a cost of resistance in terms of reproductive rate in our melittin-
and iseganan-selected cultures. Pleiotropy may limit resistance
when selection is applied from multiple AMPs: resistance to AMP
A may increase susceptibility to AMP B, consistent with our
hypothesis that simultaneous synthesis of multiple effectors by
immune systems contributes to the constraint of in vivo evolution of
immunoresistance.
Whilst we propose that multiple effectors constrain resistance to
the immune system, this is likely to be only one of numerous
interacting factors determining natural resistance. AMP resistance
will also be a function of the costs and benefits of resistance during
an infection. Simultaneously, holistic immunoresistance during
pathogenesis is unlikely to be conferred by just AMP resistance.
Benefits of AMP resistance will be low if the selection they apply is
marginal relative to that applied by other effector systems e.g.
phagocytes. It is additionally possible that bacteria have evolved
mechanisms which are induced in response to exposure to AMPs,
such as formation biofilms to limit exposure of a subset of cells.
Having corroborated previous data on the costs of AMP resistance
and expanded on it by considering costs of resistance to combined
AMPs, our selected cultures now constitute a resource which can
be used for a full economic assessment of costs and benefits of
AMP resistance in vivo.
We have demonstrated that a combination of AMPs does not
behave additively with respect to the selection imposed on S. aureus
over ecological time, since the response to selection from two
combined AMPs was not the same as the response to equivalent
selection from the constituents. This response was qualitatively
similar to that of the robust antibiotic vancomycin, whilst the
constituents of the combination behaved similarly to streptomycin.
We propose that such interactive effects are likely to be a factor to
constrain the evolution of microbial resistance to AMPs in their
natural immunological context.
Supporting Information
Figure S1 24 hr OD over the course of the experiment
averaged for the treatments. Optical Density (595 nm) of S.
aureus cultures under weekly doubling selection from a range of
antimicrobial stressors were measured daily, 24 hr after inocu-
laiton (n= 5 per treatment). Cultures showing OD595,0.05 are
assumed dead and have been excluded from means calculation.
(TIFF)
Table S1 Stressor concentrations per experiment.
(DOCX)
Methods S1 Daily OD, stressor concentrations, vanco-
mycin extinction.
(DOCX)
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